{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:28Z","timestamp":1782719068640,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07854-x","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T03:49:14Z","timestamp":1775447354000},"page":"5408-5416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zirconium-89-based PSMA PET\/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA\u2009\u2264\u20090.2 ng\/mL: A feasibility study"],"prefix":"10.1007","volume":"53","author":[{"given":"Tilman","family":"Speicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Latell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz B.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muammer","family":"Misirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"7854_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596\u2013604. https:\/\/doi.org\/10.2967\/jnumed.120.257238.","journal-title":"J Nucl Med"},{"key":"7854_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cart","year":"2021","unstructured":"de Feria Cart RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, et al. Is prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol. 2021;79:413\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.043.","journal-title":"Eur Urol"},{"key":"7854_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7854_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84:191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"7854_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-y","volume":"1","author":"GL Wright","year":"1995","unstructured":"Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18\u201328. https:\/\/doi.org\/10.1016\/1078-1439(95)00002-y.","journal-title":"Urol Oncol"},{"key":"7854_CR6","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"7854_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637\u201340. https:\/\/doi.org\/10.1016\/s0090-4295(98)00278-7.","journal-title":"Urology"},{"key":"7854_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.04.004","volume":"130","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann MA, Wieler HJ, Baues C, Kuntz NJ, Richardsen I, Schreckenberger M. The impact of 68Ga-PSMA PET\/CT and PET\/MRI on the management of prostate cancer. Urology. 2019;130:1\u201312. https:\/\/doi.org\/10.1016\/j.urology.2019.04.004.","journal-title":"Urology"},{"key":"7854_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.prnil.2020.07.008","volume":"9","author":"TN Kwan","year":"2021","unstructured":"Kwan TN, Spremo S, Teh AYM, McHarg D, Thangasamy I, Woo HH. Performance of Ga-68 PSMA PET\/CT for diagnosis and grading of local prostate cancer. Prostate Int. 2021;9:107\u201312. https:\/\/doi.org\/10.1016\/j.prnil.2020.07.008.","journal-title":"Prostate Int"},{"key":"7854_CR10","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","volume":"56","author":"M Weineisen","year":"2015","unstructured":"Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015;56:1169\u201376. https:\/\/doi.org\/10.2967\/jnumed.115.158550.","journal-title":"J Nucl Med"},{"key":"7854_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen G, Huang M, Tian R. The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis. Front Oncol. 2021;11:684629. https:\/\/doi.org\/10.3389\/fonc.2021.684629.","journal-title":"Front Oncol"},{"key":"7854_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol"},{"key":"7854_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60:786\u201393. https:\/\/doi.org\/10.2967\/jnumed.118.219501.","journal-title":"J Nucl Med"},{"key":"7854_CR14","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","volume":"48","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48:2925\u201334. https:\/\/doi.org\/10.1007\/s00259-021-05189-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7854_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bju.13616","volume":"118","author":"G Meredith","year":"2016","unstructured":"Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, et al. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118(3):49\u201355. https:\/\/doi.org\/10.1111\/bju.13616.","journal-title":"BJU Int"},{"key":"7854_CR16","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1007\/s00259-025-07292-1","volume":"52","author":"C Burgard","year":"2025","unstructured":"Burgard C, Frei M, Blickle A, Hartrampf PE, Hoffmann MA, Schreckenberger M, et al. <article-title update=\"added\">PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009\u2264\u20090.2 ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. Eur J Nucl Med Mol Imaging. 2025;52:4368\u201376. https:\/\/doi.org\/10.1007\/s00259-025-07292-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7854_CR17","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1007\/s00259-022-05925-3","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Schaefer-Schuler A, Bartholom\u00e4 M, Maus S, Petto S, Burgard C, et al. <article-title update=\"added\">[89Zr]Zr-PSMA-617 PET\/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates. Eur J Nucl Med Mol Imaging. 2022;49:4736\u201347. https:\/\/doi.org\/10.1007\/s00259-022-05925-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7854_CR18","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1007\/s00259-021-05661-0","volume":"49","author":"BM Priv\u00e9","year":"2022","unstructured":"Priv\u00e9 BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, et al. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging. 2022;49:2064\u201376. https:\/\/doi.org\/10.1007\/s00259-021-05661-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7854_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124309","volume":"21","author":"JK Yoon","year":"2020","unstructured":"Yoon JK, Park BN, Ryu EK, An YS, Lee SJ. Current perspectives on 89Zr-PET imaging. Int J Mol Sci. 2020;21(12):4309. https:\/\/doi.org\/10.3390\/ijms21124309.","journal-title":"Int J Mol Sci"},{"key":"7854_CR20","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/acs.bioconjchem.7b00325","volume":"28","author":"S Heskamp","year":"2017","unstructured":"Heskamp S, Raav\u00e9 R, Boerman O, Rijpkema M, Goncalves V, Denat F. 89Zr-immuno-positron emission tomography in oncology: state-of-the-art 89Zr radiochemistry. Bioconjug Chem. 2017;28:2211\u201323. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00325.","journal-title":"Bioconjug Chem"},{"key":"7854_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2967\/jnumed.120.250720","volume":"62","author":"KH Jung","year":"2021","unstructured":"Jung KH, Park JW, Lee JH, Moon SH, Cho YS, Lee KH. 89Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression. J Nucl Med. 2021;62:656\u201364. https:\/\/doi.org\/10.2967\/jnumed.120.250720.","journal-title":"J Nucl Med"},{"key":"7854_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.119.239558","volume":"62","author":"G van Dongen","year":"2021","unstructured":"van Dongen G, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, et al. The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals. J Nucl Med. 2021;62:438\u201345. https:\/\/doi.org\/10.2967\/jnumed.119.239558.","journal-title":"J Nucl Med"},{"issue":"2","key":"7854_CR23","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58(2):67S-76S. https:\/\/doi.org\/10.2967\/jnumed.116.186767.","journal-title":"J Nucl Med"},{"key":"7854_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697\u2013705. https:\/\/doi.org\/10.2967\/jnumed.115.161299.","journal-title":"J Nucl Med"},{"issue":"1","key":"7854_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00671-1","volume":"24","author":"F Rosar","year":"2024","unstructured":"Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A, et al. [89Zr]Zr-PSMA-617 PET\/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET\/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis. Cancer Imaging. 2024;24(1):27. https:\/\/doi.org\/10.1186\/s40644-024-00671-1.","journal-title":"Cancer Imaging"},{"issue":"1","key":"7854_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-024-00778-5","volume":"24","author":"C Burgard","year":"2024","unstructured":"Burgard C, Rosar F, Larsen E, Khreish F, Linxweiler J, Marlowe RJ, et al. Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET\/CT in early biochemical recurrence of prostate cancer. Cancer Imaging. 2024;24(1):132. https:\/\/doi.org\/10.1186\/s40644-024-00778-5.","journal-title":"Cancer Imaging"},{"issue":"9","key":"7854_CR27","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1007\/s00259-023-06241-0","volume":"50","author":"F Rosar","year":"2023","unstructured":"Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, et al. Detection efficacy of [89Zr]Zr-PSMA-617 PET\/CT in [68Ga]Ga-PSMA-11 PET\/CT-negative biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50(9):2899\u2013909. https:\/\/doi.org\/10.1007\/s00259-023-06241-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7854_CR28","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.18632\/oncotarget.27239","volume":"10","author":"MA Hoffmann","year":"2019","unstructured":"Hoffmann MA, Buchholz HG, Wieler HJ, H\u00f6fner T, M\u00fcller-H\u00fcbenthal J, Trampert L, et al. The positivity rate of 68Gallium-PSMA-11 ligand PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Oncotarget. 2019;10:6124\u201337. https:\/\/doi.org\/10.18632\/oncotarget.27239.","journal-title":"Oncotarget"},{"issue":"8","key":"7854_CR29","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1007\/s00259-024-06674-1","volume":"51","author":"Y Wang","year":"2024","unstructured":"Wang Y, Dong L, Zhao H, Li L, Huang G, Xue W, et al. <article-title update=\"added\">The superior detection rate of total-body [68Ga]Ga-PSMA-11 PET\/CT compared to short axial field-of-view [68Ga]Ga-PSMA-11 PET\/CT for early recurrent prostate cancer patients with PSA\u2009<\u20090.2\u00a0ng\/mL after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51(8):2484\u201394. https:\/\/doi.org\/10.1007\/s00259-024-06674-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7854_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051376","volume":"15","author":"C Burgard","year":"2023","unstructured":"Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ, et al. Detection efficacy of 68Ga-PSMA-11 PET\/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-year, two-center \u201creal-world\u201d experience. Cancers (Basel). 2023;15:1376. https:\/\/doi.org\/10.3390\/cancers15051376.","journal-title":"Cancers (Basel)"},{"key":"7854_CR31","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1007\/s00259-025-07255-6","volume":"52","author":"A Di Giorgio","year":"2025","unstructured":"Di Giorgio A, Siepe G, Serani F, Di Franco M, Malizia C, Castellucci P, et al. Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. Eur J Nucl Med Mol Imaging. 2025;52:3720\u20139. https:\/\/doi.org\/10.1007\/s00259-025-07255-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7854_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.semradonc.2025.05.004","volume":"35","author":"V Dragonetti","year":"2025","unstructured":"Dragonetti V, Colandrea M, Travaini L, Air\u00f2 Farulla LS, Ceci F, Mattana F. PSMA-PET guided radiotherapy in prostate cancer: a critical review of current applications and future directions. Semin Radiat Oncol. 2025;35:317\u201324. https:\/\/doi.org\/10.1016\/j.semradonc.2025.05.004.","journal-title":"Semin Radiat Oncol"},{"key":"7854_CR33","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00259-023-06185-5","volume":"50","author":"N Solomonidou","year":"2023","unstructured":"Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, et al. PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA\u2009<\u20090.2\u00a0ng\/ml. Eur J Nucl Med Mol Imaging. 2023;50:2529\u201336. https:\/\/doi.org\/10.1007\/s00259-023-06185-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7854_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.eururo.2015.10.009","volume":"69","author":"N Fossati","year":"2016","unstructured":"Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, et al. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2016;69:728\u201333. https:\/\/doi.org\/10.1016\/j.eururo.2015.10.009.","journal-title":"Eur Urol"},{"key":"7854_CR35","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1200\/jco.2016.67.9647","volume":"34","author":"RD Tendulkar","year":"2016","unstructured":"Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016;34:3648\u201354. https:\/\/doi.org\/10.1200\/jco.2016.67.9647.","journal-title":"J Clin Oncol"},{"key":"7854_CR36","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","volume":"26","author":"A Pozdnyakov","year":"2023","unstructured":"Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:240\u20138. https:\/\/doi.org\/10.1038\/s41391-022-00544-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7854_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euo.2022.01.001","volume":"5","author":"D Meijer","year":"2022","unstructured":"Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, et al. Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. Eur Urol Oncol. 2022;5:146\u201352. https:\/\/doi.org\/10.1016\/j.euo.2022.01.001.","journal-title":"Eur Urol Oncol"},{"key":"7854_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.118.212563","volume":"60","author":"NS Schmidt-Hegemann","year":"2019","unstructured":"Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, et al. Outcome After PSMA PET\/CT\u2013Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. J Nucl Med. 2019;60:227\u201333. https:\/\/doi.org\/10.2967\/jnumed.118.212563.","journal-title":"J Nucl Med"},{"key":"7854_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.euo.2021.01.007","volume":"4","author":"L Valle","year":"2021","unstructured":"Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, et al. Use and Impact of Positron Emission Tomography\/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. Eur Urol Oncol. 2021;4:339\u201355. https:\/\/doi.org\/10.1016\/j.euo.2021.01.007.","journal-title":"Eur Urol Oncol"},{"key":"7854_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.euf.2024.11.006","volume":"11","author":"C Zamboglou","year":"2025","unstructured":"Zamboglou C, Staus P, Wolkewitz M, Peeken JC, Ferentinos K, Strouthos I, et al. Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography\u2013guided Salvage Radiotherapy Following Prostatectomy. Eur Urol Focus. 2025;11:242\u201350. https:\/\/doi.org\/10.1016\/j.euf.2024.11.006.","journal-title":"Eur Urol Focus"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07854-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:47:06Z","timestamp":1782715626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07854-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7854"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07854-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study was approved by the responsible Institutional Review Board (\u00c4rztekammer des Saarlandes\/Saarbr\u00fccken; ethics committee permission number 170\/22). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for publication of any resulting data in anonymized form was obtained from all individual participants included in the analysis. The present cohort partially overlaps with a previously published dataset from our institution affecting 3 patients [\n                      \n                      ,\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}